vs
Magnera Corp（MAGN）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Magnera Corp的季度营收约是Royalty Pharma plc的1.3倍（$792.0M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs -4.3%，领先38.7%），Magnera Corp同比增速更快（12.8% vs 4.8%），过去两年Magnera Corp的营收复合增速更高（54.9% vs 4.6%）
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
MAGN vs RPRX — 直观对比
营收规模更大
MAGN
是对方的1.3倍
$622.0M
营收增速更快
MAGN
高出8.0%
4.8%
净利率更高
RPRX
高出38.7%
-4.3%
两年增速更快
MAGN
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $792.0M | $622.0M |
| 净利润 | $-34.0M | $214.2M |
| 毛利率 | 12.2% | — |
| 营业利润率 | 1.8% | 62.4% |
| 净利率 | -4.3% | 34.4% |
| 营收同比 | 12.8% | 4.8% |
| 净利润同比 | 43.3% | 2.9% |
| 每股收益（稀释后） | $-0.95 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAGNRPRX
| Q4 25 | $792.0M | $622.0M | ||
| Q3 25 | — | $609.3M | ||
| Q2 25 | $839.0M | $578.7M | ||
| Q1 25 | $824.0M | $568.2M | ||
| Q4 24 | $702.0M | $593.6M | ||
| Q3 24 | $332.1M | $564.7M | ||
| Q2 24 | $556.0M | $537.3M | ||
| Q1 24 | $558.0M | $568.0M |
净利润MAGNRPRX
| Q4 25 | $-34.0M | $214.2M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | $-18.0M | $30.2M | ||
| Q1 25 | $-41.0M | $238.3M | ||
| Q4 24 | $-60.0M | $208.2M | ||
| Q3 24 | $-15.2M | $544.0M | ||
| Q2 24 | $19.0M | $102.0M | ||
| Q1 24 | $14.0M | $4.8M |
毛利率MAGNRPRX
| Q4 25 | 12.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 6.2% | — |
营业利润率MAGNRPRX
| Q4 25 | 1.8% | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | 1.5% | 36.3% | ||
| Q1 25 | 0.5% | 94.0% | ||
| Q4 24 | -3.1% | 60.9% | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 3.1% | 50.2% | ||
| Q1 24 | 3.8% | -13.0% |
净利率MAGNRPRX
| Q4 25 | -4.3% | 34.4% | ||
| Q3 25 | — | 47.3% | ||
| Q2 25 | -2.1% | 5.2% | ||
| Q1 25 | -5.0% | 41.9% | ||
| Q4 24 | -8.5% | 35.1% | ||
| Q3 24 | -4.6% | 96.3% | ||
| Q2 24 | 3.4% | 19.0% | ||
| Q1 24 | 2.5% | 0.8% |
每股收益（稀释后）MAGNRPRX
| Q4 25 | $-0.95 | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | $-0.51 | $0.07 | ||
| Q1 25 | $-1.15 | $0.55 | ||
| Q4 24 | $-1.69 | $0.46 | ||
| Q3 24 | $-0.33 | $1.21 | ||
| Q2 24 | $0.60 | $0.23 | ||
| Q1 24 | $0.44 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $264.0M | $618.7M |
| 总债务越低越好 | $1.9B | $9.0B |
| 股东权益账面价值 | $1.0B | $9.7B |
| 总资产 | $3.9B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.86× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资MAGNRPRX
| Q4 25 | $264.0M | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | $276.0M | $631.9M | ||
| Q1 25 | $282.0M | $1.1B | ||
| Q4 24 | $215.0M | $929.0M | ||
| Q3 24 | $230.0M | $950.1M | ||
| Q2 24 | $33.9M | $1.8B | ||
| Q1 24 | $30.2M | $843.0M |
总债务MAGNRPRX
| Q4 25 | $1.9B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | $2.0B | $8.0B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $2.0B | $7.6B | ||
| Q3 24 | $2.0B | $7.6B | ||
| Q2 24 | $877.4M | $7.6B | ||
| Q1 24 | $884.7M | $6.1B |
股东权益MAGNRPRX
| Q4 25 | $1.0B | $9.7B | ||
| Q3 25 | — | $9.6B | ||
| Q2 25 | $1.1B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $2.1B | $10.3B | ||
| Q2 24 | $2.4B | $9.8B | ||
| Q1 24 | $2.4B | $9.9B |
总资产MAGNRPRX
| Q4 25 | $3.9B | $19.6B | ||
| Q3 25 | — | $19.3B | ||
| Q2 25 | $4.1B | $18.3B | ||
| Q1 25 | $4.1B | $17.6B | ||
| Q4 24 | $4.0B | $18.2B | ||
| Q3 24 | $2.8B | $18.0B | ||
| Q2 24 | $1.5B | $17.7B | ||
| Q1 24 | $1.5B | $16.1B |
负债/权益比MAGNRPRX
| Q4 25 | 1.86× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | 1.77× | 0.84× | ||
| Q1 25 | 1.83× | 0.78× | ||
| Q4 24 | 1.80× | 0.74× | ||
| Q3 24 | 0.91× | 0.74× | ||
| Q2 24 | 0.37× | 0.78× | ||
| Q1 24 | 0.36× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-13.0M | — |
| 自由现金流率自由现金流/营收 | -1.6% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MAGNRPRX
| Q4 25 | $2.0M | $827.1M | ||
| Q3 25 | — | $702.6M | ||
| Q2 25 | $0 | $364.0M | ||
| Q1 25 | $65.0M | $596.1M | ||
| Q4 24 | $-58.0M | $742.5M | ||
| Q3 24 | $12.2M | $703.6M | ||
| Q2 24 | $38.0M | $658.2M | ||
| Q1 24 | $20.0M | $664.6M |
自由现金流MAGNRPRX
| Q4 25 | $-13.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $42.0M | — | ||
| Q4 24 | $-74.0M | — | ||
| Q3 24 | $3.6M | — | ||
| Q2 24 | $23.0M | — | ||
| Q1 24 | $12.5M | — |
自由现金流率MAGNRPRX
| Q4 25 | -1.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | -10.5% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 2.2% | — |
资本支出强度MAGNRPRX
| Q4 25 | 1.9% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 1.3% | — |
现金转化率MAGNRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 2.00× | 6.45× | ||
| Q1 24 | 1.43× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAGN
| Other | $451.0M | 57% |
| United States And Canada | $341.0M | 43% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
